Latest Fusion protein Stories

2010-05-20 07:50:00

Researchers at the Biodesign Institute at Arizona State University have developed a much faster and simpler way of making synthetic antibodies, by carrying out the usual steps in reverse.

2010-01-07 08:12:00


2009-12-14 23:23:35

A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).

2009-10-21 08:27:00

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client.

2009-04-02 06:00:00

OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an antibody-coliphage pIII fusion protein, to identify tumor associated antigens on cells by negative selection.

2008-10-15 12:00:34

Immunomedics, a biopharmaceutical company, has received a new US patent that covers the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on B-lymphocytes, leukemias, and lymphomas.

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S.

2008-09-25 09:00:54

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc., a privately held Los Angeles-based biotechnology company developing oncology products, today announced they have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr.

2005-08-29 14:47:08

Origen Therapeutics today announced the first published scientific report of fully functional, human sequence monoclonal antibodies (mAbs) produced in chickens. The antibodies were expressed solely in the chicken oviduct and deposited into egg white in concentrations of 1-3 milligrams per egg. Moreover, antibodies produced in this manner demonstrated 10-100 fold greater cell-killing ability (ADCC) compared to therapeutic antibodies produced by conventional cell culture methods.

Word of the Day
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.